On April 11, 2019, Shanghai Luoqi Bio-pharmaceutical Technology Co., Ltd. won the bid for the 2019 "Science and Technology Innovation Action Plan" in the field of biomedicine science and technology support project in Shanghai.

About novamab

Shanghai Novamab Biomedical Technology Co., Ltd. (Novamab), established in Shanghai International Medical Park, Pudong New Area, Shanghai on October 16, 2017, is a research and development company focusing on the whole industrial chain of nano-antibody biological drugs, focusing on the industrialization of innovative biological drug achievements and the research and development of targeted immune anti-cancer drugs. At present, the company has successfully built a product chain that includes multiple new drug varieties of nanoantibody, covering the fields of tumor, fundus disease, autoimmune disease, cardiovascular disease and other diseases, and has formed strategic partnerships with many well-known enterprises at home and abroad. Many cooperation projects have been promoted to clinical phase III. The company focuses on establishing an integrated, systematic and comprehensive professional development platform, and is committed to the research and development and take-off of nano-antibody drugs.

公司官网：http://www.novamab.com/